Papeix C, Vidal J-S, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, Lebrun C, Moreau T, Vermersch P, Fontaine B, Lyon-Caen O, Gout O
Department of Neurology, Hôpital de la Salpêtrière, Paris, France.
Mult Scler. 2007 Mar;13(2):256-9. doi: 10.1177/1352458506070732. Epub 2007 Jan 29.
To determine long-term treatment (LTT) of neuromyelitis optica (NMO), we retrospectively reviewed therapies of 26 patients with NMO followed in five French neurological departments. To assess LTT efficacy, the probability of relapse free after LTT was analysed. Patients were divided into two groups according to the first treatment receiving interferon beta (IFN Group, seven patients) or immunosuppressants (IS Group, 19 patients). The probability of relapse was significantly lower in the IS Group (P =0.0007). From our results, interferon beta is not recommended, and one of the best current therapeutic options for NMO appears to be immunosuppressants.
为确定视神经脊髓炎（NMO）的长期治疗方案，我们回顾性分析了法国五个神经科收治的26例NMO患者的治疗情况。为评估长期治疗的疗效，分析了长期治疗后无复发的概率。根据首次治疗使用的药物，将患者分为两组，即使用β干扰素的患者（干扰素组，7例）和使用免疫抑制剂的患者（免疫抑制剂组，19例）。免疫抑制剂组的复发概率显著更低（P =0.0007）。根据我们的研究结果，不推荐使用β干扰素，目前NMO最佳的治疗选择之一似乎是免疫抑制剂。
